Physician profile
Vinitha Nareddy
NPI 1144631193
$11,047.45
in general payments reported to CMS, 2019-2025
55 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,313 · 2022: $2,236 · 2023: $2,625 · 2024: $2,749 · 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,498.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,295.41 | 2021-2025 | |
| Novo Nordisk INC | $1,282.23 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,086.58 | 2021-2025 | |
| Lilly USA, LLC | $837.47 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $569.12 | 2021-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $496.17 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Esperion Therapeutics, INC. | $463.18 | 2021-2025 | Nexletol |
| Axsome Therapeutics, INC. | $450.21 | 2022-2025 | Auvelity, Sunosi |
| Glaxosmithkline, LLC. | $304.44 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Corium, LLC | $247.76 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $238.80 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.28 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $223.97 | 2023-2025 | Rexulti, Abilify Maintena |
| Dexcom, INC. | $223.43 | 2023-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $216.28 | 2022 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.13 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $195.65 | 2022-2025 | |
| Astellas Pharma US INC | $179.31 | 2023-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $177.68 | 2021-2025 | Rexulti, Vyepti |
| Antares Pharma, INC. | $176.07 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $171.56 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $135.24 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $130.88 | 2022-2024 | Strensiq |
| Janssen Pharmaceuticals, INC | $128.64 | 2021-2023 | Xarelto |
| Kvk-Tech, INC. | $105.81 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $97.47 | 2023-2024 | Ajovy |
| Daiichi Sankyo INC. | $91.39 | 2021-2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $87.88 | 2021-2024 | Eliquis |
| Alnylam Pharmaceuticals INC. | $80.48 | 2021-2022 | |
| Amarin Pharma, INC. | $78.91 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $69.89 | 2022-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $60.38 | 2024-2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $59.77 | 2022-2024 | Nuzyra |
| Supernus Pharmaceuticals, INC. | $59.32 | 2022-2023 | Xyosted, Qelbree |
| Biohaven Pharmaceuticals, INC. | $55.02 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $42.64 | 2023 | |
| Noven Therapeutics, LLC | $41.03 | 2024 | Xelstrym |
| Boston Scientific Corporation | $38.85 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Eisai INC. | $34.79 | 2021-2025 | |
| Renalytix Ai, INC. | $33.93 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Harmony Biosciences LLC | $32.59 | 2024 | |
| Merck Sharp & Dohme LLC | $30.84 | 2022-2023 | Verquvo, Belsomra |
| Tolmar, INC. | $28.95 | 2024-2025 | Jatenzo |
| Halozyme INC | $28.89 | 2023 | |
| Neos Therapeutics, LP | $28.59 | 2024 | Adzenys Xr-Odt |
| Kyowa Kirin, INC. | $27.79 | 2023 | Crysvita |
| Horizon Therapeutics Plc | $23.97 | 2023 | Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.72 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $18.40 | 2024 | Contrave |
| Collegium Pharmaceutical, INC. | $16.92 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.08 | 2022 | |
| Genentech USA, INC. | $14.00 | 2021 | |
| Abbott Laboratories | $13.88 | 2025 | Eterna |
| Acerus Pharmaceuticals Corporation | $13.56 | 2022 | |
| Almatica Pharma LLC | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinitha Nareddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.